Garland R J, Groves S J, Diamanti P, West S E, Winship K L, Virgo P F, Robinson S P, Oakhill A, Cornish J M, Pamphilon D H, Marks D I, Goulden N J, Steward C G
Department of Pathology and Microbiology, University of Bristol, University Walk, Bristol, UK.
Bone Marrow Transplant. 2005 Aug;36(3):237-44. doi: 10.1038/sj.bmt.1705049.
CAMPATH-1H (C-1H) is widely used in vivo and / or in vitro for T cell depletion in hematopoietic SCT. This humanised monoclonal antibody is specific for CD52, a marker coexpressed on the majority of human lymphocytes with CD48 and other glycosylphosphatidyl-inositol (GPI) anchored proteins. We detected CD52 / CD48 dual expression on >99% of CD3(+) lymphocytes from normal individuals and all 15 post-SCT patients whose transplants did not utilise C-1H. By contrast, 23 / 26 patients with transplants involving C-1H (in vivo, in vitro or both) exhibited populations lacking CD52 expression that accounted for 49.7% (4.2-86.2%) of the CD3+ lymphocytes (median and range) in samples evaluated at a median of 2 months post-SCT. Most CD52- cells also lacked CD48 expression. These GPI- T cells were of either donor or mixed donor / recipient origin. They were predominant in the early months after SCT at times of profound lymphopenia and inversely correlated with the recovery of the absolute lymphocyte count (r= - 0.663, P<0.0001). The presence of CD52- cells has been correlated previously with clinical outcome after CAMPATH therapy for both malignant and nonmalignant diseases.
CAMPATH-1H（C-1H）在体内和/或体外广泛用于造血干细胞移植中的T细胞清除。这种人源化单克隆抗体对CD52具有特异性，CD52是一种在大多数人类淋巴细胞上与CD48和其他糖基磷脂酰肌醇（GPI）锚定蛋白共表达的标志物。我们检测到正常个体以及所有15例未使用C-1H进行移植的造血干细胞移植后患者中，>99%的CD3(+)淋巴细胞上存在CD52/CD48双表达。相比之下，26例接受涉及C-1H移植（体内、体外或两者皆有）的患者中，有23例出现了缺乏CD52表达的细胞群，这些细胞群占造血干细胞移植后中位2个月时所评估样本中CD3+淋巴细胞的49.7%（4.2 - 86.2%）（中位数和范围）。大多数CD52阴性细胞也缺乏CD48表达。这些GPI阴性T细胞来源于供体或供体/受体混合来源。它们在造血干细胞移植后的最初几个月、淋巴细胞严重减少时占主导地位，并且与绝对淋巴细胞计数的恢复呈负相关（r = - 0.663，P<0.0001）。先前已有研究表明，CD52阴性细胞的存在与CAMPATH治疗恶性和非恶性疾病后的临床结局相关。
